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EDITORIAL
THE DOCUMENT OF THE AMERICAS:
GOOD CLINICAL PRACTICES FOR REGULATORY AUTHORITIES
In 1996, when the Guidelines for Good Clinical
Practices of the International Conference on
Harmonization (ICH) were adopted, they sought to
facilitate the actions of regulatory authorities over the
different players of clinical research.  These guidelines
were created and incorporated to the legislation of the
three regions of the world (United States, European
Union, and Japan) where most of the drugs, vaccines,
biologicals, diagnostic tests, and medical devices are
produced. The regulatory authorities from those three
regions are characterized for their extensive technical
capacity to execute their mission of promoting
technological advances and protecting communities.
However, undertaking this task has been difficult, partially
because the ICH Good Clinical Practices defined
responsibilities for Ethical Committees, Sponsors, and
Investigators; but the regulatory authorities did not
precise their own responsibilities or indicate how they
would accomplish their duties in that document and,
therefore, did not reach the harmonization of their
practices in those subjects.
Certainly, this point is one of the major advances
offered by the Document of the Americas on Good
Clinical Practices: helping the regulatory authorities of
the continent to establish a common platform on how to
perform their duties regarding clinical research. The
possibilities that this common regulatory methodology
offers to the authorities from our countries, with greater
limitations in budget and in human resources than their
ICH counterparts, are promising: it might allow unified
staff training, conduction of joint inspections and, even,
thinking of a mutual recognition for the actions of the
authorities in each country, as occurred in Europe more
than three decades ago. However, the promises have
not been delivered in the desired extension: despite the
March 2005 meeting held in the Dominican Republic,
where the Document of the Americas was published,
was held in March, 2005, it means almost five years ago,
few countries, like Argentina (2007), Brazil (2008), and
Colombia (2008) have incorporated this document into
their own regulations.
There are interesting experiences such as the Brazilian
federal government promotion for the creation of centers
to lead clinical research of public health interest in
university hospitals, at the same time that the federal
regulatory authority implements the new regulation on
requirements for clinical research centers. In such
experience, the government is not limited to imposing a
new standard, but endorses and actively supports
universities and the academic community as quality
references in research. That allows clinical research to
not only become just an additional profitable activity of
a few private players, but also builds capacity to solving
regional problems. Transferring of such experiences
might be easier with the adoption of common platforms
within the region.
Having strong regulatory authorities is necessary to
move forward from a provider of volunteers, data, and
samples for multinational companies to becoming a
leader in the solutions for our regional health problems,
created from our universities and industries. But the
need is even more urgent: the development of innovative
products for our health problems created either by
multinationals or within the region, requires technically
capable interlocutors with close knowledge of the needs
of our community.
The Document of the Americas, pioneer initiative of
the Pan American Network for Drug Regulatory
Harmonization (PANDRH), can be the first step towards
a future common regional agency, like the European
Medicine Agency (EMEA); a regional agency that
would be able to offer technical capacity to the member
countries and represent the region in future discussions
on research regulation.
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